Back to Journals » Medical Devices: Evidence and Research » Volume 9

Management of fecal incontinence - focus on a vaginal insert for bowel control

Authors Sokol E

Received 2 February 2016

Accepted for publication 7 April 2016

Published 10 May 2016 Volume 2016:9 Pages 85—91

DOI https://doi.org/10.2147/MDER.S86483

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Eric R Sokol

Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, USA

Abstract: Fecal incontinence, also referred to as accidental bowel leakage, is a debilitating condition that impacts quality of life in a significant number of women. Current treatments for fecal incontinence include behavioral modification, biofeedback, drug therapy, and invasive surgical procedures. However, these treatments have suboptimal efficacy due to patient adherence, variability of presentation across patients, cost, and additional health risks. A vaginal bowel control system (EclipseTM System) was developed to offer a low-risk, effective, and patient-managed approach to treating accidental bowel leakage. The vaginal bowel control system consists of a vaginal insert and user-controlled, pressure-regulated pump. Once inflated, the balloon of the vaginal insert is directed posteriorly to occlude the rectum, allowing the woman to immediately regain control of bowel function. This article will introduce the design evolution and feasibility studies of the Eclipse System. In addition, this review will discuss the results from a recent clinical trial that demonstrated the safety and efficacy of the vaginal bowel control system in managing fecal incontinence and other symptoms of bowel dysfunction.

Keywords: accidental bowel leakage, fecal urgency, vaginal bowel control system, Eclipse System, bowel function

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Silencing of carboxypeptidase E inhibits cell proliferation, tumorigenicity, and metastasis of osteosarcoma cells

Fan SL, Li X, Li LM, Wang LG, Du ZZ, Yang Y, Zhao JS, Li Y

OncoTargets and Therapy 2016, 9:2795-2803

Published Date: 10 May 2016

miR-125b inhibited epithelialal–mesenchymal transition of triple-negative breast cancer by targeting MAP2K7

Hong LQ, Pan F, Jiang HF, Zhang LH, Liu YH, Cai CS, Hua CZ, Luo X, Sun JH, Chen ZJ

OncoTargets and Therapy 2016, 9:2639-2648

Published Date: 4 May 2016